Results 51 to 60 of about 4,504 (155)

Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation

BMC Infectious Diseases, 2012
Background Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) are at high risk of acquiring fungal infections. Antifungal prophylaxis shortly after transplantation is therefore indicated, but data for pediatric patients under 12
Döring Michaela, Müller Carsten, Johann Pascal-David, Erbacher Annika, Kimmig Astrid, Schwarze Carl-Philipp, Lang Peter, Handgretinger Rupert, Müller Ingo   +8 more
doaj   +1 more source

Occurrence of infections in dogs receiving ciclosporin in a single‐centre UK referral population

Journal of Small Animal Practice, EarlyView.
Objectives The study aimed (a) to describe the occurrence and nature of new infections in dogs receiving oral ciclosporin and (b) to identify any risk factors associated with the development of a new infection whilst receiving ciclosporin. Materials and Methods In this retrospective cohort study, medical records of dogs presented to a private UK ...
S. Dormon, J. Walker, G. Gallow, L. Goonan, T. Sparks, A. Paul   +5 more
wiley   +1 more source

Posaconazole in immunocompromised pediatric patients

, 2018
Posaconazole is a broad-spectrum triazole widely used to prevent and treat invasive mycoses in adults. Since it received marketing authorization more than a decade ago, many authors have reported on its off-label use in pediatric patients, despite the ...
Vicenzi, Edoardo Bruno, Simone Cesaro, Cesaro, Simone, Edoardo Bruno Vicenzi   +3 more
core   +1 more source

Combinations of posaconazole and tacrolimus are effective against infections with azole-resistant Aspergillus fumigatus

Frontiers in Cellular and Infection Microbiology
BackgroundSolid organ transplant recipients on immunosuppressants such as tacrolimus are at increased risk of developing pulmonary aspergillosis, a severe to deadly complication with limited treatment options, especially against azole-resistant strains ...
Eliane Vanhoffelen, Tine Van Win, Eva Van Braeckel, Eva Van Braeckel, Agustin Reséndiz-Sharpe, Bruno P. A. Cammue, Bruno P. A. Cammue, Katrien Lagrou, Katrien Lagrou, Karin Thevissen, Greetje Vande Velde   +10 more
doaj   +1 more source

Posaconazole conformation.

, 2013
A. Fragments of the Fo-Fc electron density map (grey mesh) in chains A, B and D calculated with the posaconazole coordinates omitted from the input file. B, C.
Matthew P. Jacobson (174588), James H. McKerrow (113918), Christophe Guilbert (365836), Siegfried S. F. Leung (365835), Larissa M. Podust (145743), Chiung-Kuang Chen (145721)   +5 more
core   +1 more source

Invasive fungal infection following venetoclax and posaconazole co-administration

, 2023
The co-administration of venetoclax, a BCL-2 inhibitor, with a mould-active azole, such a posaconazole, has potential to both prevent invasive fungal infection (IFI) and reduce the required treatment dose, and cost, of venetoclax. Posaconazole drug-level
Reynolds, G, Urbancic, KF, Fong, CY, Trubiano, JA   +3 more
core   +1 more source

Design Considerations for Polymer–Deep Eutectic Solvent Hybrid Systems for Transdermal Drug Delivery

Journal of Applied Polymer Science, Volume 143, Issue 40, October 20, 2026.
Deep eutectic solvents (DESs) act as tunable, green excipients that modulate polymer structure–property relationships to enhance drug solubility, skin permeation, stability, and controlled release. Through hydrogen‐bond interactions, DES–polymer hybrid systems enable improved transdermal performance, offering a rational, design‐driven platform for ...
Madhavi Kailas Kapale, Madhur Kulkarni, Pranav J. Shah, Furqan A. Maulvi   +3 more
wiley   +1 more source

Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing : How to optimize ibrutinib dose during posaconazole treatment

, 2023
Aims: Ibrutinib is used in the treatment of certain B-cell malignancies. Due to its CYP3A4-mediated metabolism and highly variable pharmacokinetics, it is prone to potentially harmful drug-drug interactions.Methods: In a randomized, placebo-controlled ...
Tornio, Aleksi, Olkkola, Aleksi M., Kiiski, Johanna I., Niemi, Mikko, Hauta-aho, Milka, Neuvonen, Pertti J., Neuvonen, Mikko, Backman, Janne T., Tapaninen, Tuija, Lapatto-Reiniluoto, Outi   +9 more
core   +1 more source

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection

Biomedicines, 2017
Mortality and morbidity due to invasive fungal infections have increased over the years. Posaconazole is a second-generation triazole agent with an extended spectrum of activity, which shows a high interindividual variability in its plasma levels ...
Sarah Allegra, Giovanna Fatiguso, Silvia De Francia, Fabio Favata, Elisa Pirro, Chiara Carcieri, Amedeo De Nicolò, Jessica Cusato, Giovanni Di Perri, Antonio D’Avolio   +9 more
doaj   +1 more source

Posaconazole Treatment Schedule.

, 2013
Posaconazole Treatment Schedule.
Joris Veltman (431438), Jordan Dimitrakoff (431442), Adam P. Fagin (147181), Theo S. Plantinga (164719), Emeric F. Bojarski (431436), Mihai G. Netea (105648), Alexander Hoischen (195016), Adam C. Strauss (431437), Victor J. Anciano Granadillo (431440), Stephen A. Allsop (431439), Arsani William (431441)   +10 more
core   +1 more source